<i>EGFR/KRAS/BRAF</i> Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases

Abstract

The possibility of differences in the mutational status of EGFR, KRAS, BRAF between primary tumors and corresponding lymph node metastases should be considered whenever these mutations are used for the selection of patients for EGFR-directed tyrosine kinase inhibitor therapy.